order up

Restaurant-driven app focuses on Houston's food scene

Crityk's main goal is to be a marketing asset to restaurants. Getty Images

One night, Sumit Sikka was on a quest to find the best Moscow Mule in Santa Monica. He couldn't find anything helpful online, and when he finally did get a good recommendation, he was already done for the night.

It was through this experience that Sikka knew he wanted to make a restaurant finder app, but he wanted to do something different from Yelp or Google Reviews. On those platforms, a restaurant can get crushed by a bad review that provides false information. So, when he started getting the ball rolling on Crityk, he realized he needed to give the restaurants a voice.

"That was kind of the first big pivot," Sikka says. "First, we had an app based on user content. Then we pivoted to have content curated by the restaurant. For the first time ever, the restaurant gets to create their own profile."

The app launched on November 18 and has over 700 restaurant profiles live. There are 250 here in Houston, and 25 are clients, meaning they pay Crityk and have exclusive marketing opportunities, like promoting events — something most restaurants struggle to engage customers with.

"Restaurants do so much marketing, but they do the majority of it inside the restaurant," Sikka says. "Who's not going into your restaurant and not seeing that?"

Crityk users can log into the app and find different restaurant events around town to attend. Users can upload images of food from different restaurants. They rate the specific menu item, rather than the restaurant as a whole. Then, restaurants can link that photo to the specific menu item. Instead of comments on the picture, users can engage with hashtags. Any comments a user might have would go directly to the establishment to be resolved.

Another priority for Crityk is to have photos of every menu item the restaurant offers as well as complete dietary information. It's becoming more and more important for diners to know about vegan, gluten-free, etc. options before getting to the restaurant only to be disappointed with the selection.

Investing in Houston
While the idea came about in California, Sikka, who has a sister who lives in The Woodlands, took a trip to Houston to feel out consumer interest in the app. He hosted an event with a local restaurant and some influencers. The app kind of just exploded in town, Sikka says.

"I packed up some of my bags and decided to try here in Houston," Sikka says." It's a lot easier to get to decision makers here in Houston than in LA."

The development team is still based in India, and Crityk's co-founder, John Kegel, is still based in California. However, Sikka works out of Station Houston, something he says has been an extremely valuable. He says he's made some valuable connections through both Station and the Texas Restaurant Association.

"I think Houston is a phenomenal city to get started in. It's a big city, but it has the feeling of a small city."

Second course?
Still under two months old, the app has a lot of improvements and expansions in the works. Sikka says he wants to double the number of restaurant profiles to 500 by summer. He'd also like to grow the number of paying clients on the site, which would include more restaurants with a full photo menu on the app for users to browse.

Photo-first

Screenshot via the Crityk app

Users can upload pictures of their meals. Then, restaurants can tag it to a menu item.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted